Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Date:10/29/2008

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter financial results after the market closes on Thursday, November 6, 2008.

Cadence management will host a conference call and live webcast to discuss the financial results and provide a clinical program update on Thursday, November 6, 2008 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 866-816-1982 (domestic) or 816-581-1712 (international). To access the webcast, please visit the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
2. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2008
7. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
8. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., , NOVATO, Calif., Nov. 30 /PRNewswire-Firs...MRN ) announced today that the Food and Drug Admin...n for 3,4-diaminopyridine (3,4-DAP), amifampridine...t Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has p...E.U. Also, in October 2009, the Committee for Med...
(Date:11/30/2009)..., , BOSTON and COPENHAGEN, Nov. 30 /PRNew...) announced today that the Harvard Medical School ... recognized as a MicroRNA Screening Center of Exce...Medical School, and associated hospitals and insti...lecule and RNAi libraries. ,, MicroRNAs are a n...
(Date:11/30/2009)..., , AMSTERDAM,...he world,s,leading publisher of scientific, medica...nced a major re-launch of Embase, its comprehensiv...indexed records from more than 7,000,active, peer ...ed a key role in the advancement of new biomedical...
(Date:11/27/2009)..., , DURHAM, N.C., Nov. 27 /PRNewswire...k, will initiate water-soluble carbon nanotube-bas.... The water-soluble carbon nanotubes, which have f...ugation with cancer drugs, was developed in partne...he conjugated carbon nanotubes serves as a drug de...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...sedly a banner year for venture capital investment...ers MoneyTree report, which is based on data from ... what does this mean for the life science industry... more particularly, what does it mean for the Midw...rill down to this level and find out (I can hear t...
... it again. He,s making sensational, not entirely a...business based on current conditions, which is nic...rd Business Review published an article by Carr ti...s that IT is now ubiquitous and available to all w...inable competitive advantage. , ,Even discounting ...
...ring we just escaped January a notoriously depres... the cold, dark and dank weather thats no surpris...t January 24 (just one week ago) was the most depr...reneurs already bear an extra psychological burden...sion might have escalated last month for reasons t...
Other Biology Technology:Life-science sector grabbed VC investment in 2004 2Life-science sector grabbed VC investment in 2004 3Whining should not get in the way of innovation 2Whining should not get in the way of innovation 3Post-January, tech entrepreneurs have reasons to be depressed 2Post-January, tech entrepreneurs have reasons to be depressed 3Post-January, tech entrepreneurs have reasons to be depressed 4
(Date:12/1/2009)...s an ,abominable mystery, and it is a question whi... when did flowering plants evolve and how did they...dy in Ecology Letters reveals the evolutionary t... a major competitive advantage over rival species,..., The study, by Dr Tim Brodribb and Dr Taylor Fi...
(Date:11/30/2009)... review of the state of Antarctica,s climate and i...blished this week (Tuesday 1 December) by the Scie...e review - Antarctic Climate Change and the Enviro...ontinent, identifies areas for future scientific r...olicy makers have about Antarctic melting, sea-lev...
(Date:11/30/2009)...of Pittsburgh team overcame a major hurdle plaguin...hat could lead to more efficient catalysts used to...c. The researchers reported Nov. 29 in Nature Mat...e stability in metallic nanoparticles, the vaunted...lity to extreme heat. , Gtz Veser, an associate ...
Breaking Biology News(10 mins):How did flowering plants evolve to dominate Earth? 2First comprehensive review of the state of Antarctica's climate 2First metallic nanoparticles resistant to extreme heat 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 1Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 2Sherman Oaks Hospital Opens New Cardiac Catheterization Laboratory and Reopens Behavioral Health Facility for Seniors 55349 3Iowa Drug Card a Huge Success With Iowans 55345 1Iowa Drug Card a Huge Success With Iowans 55345 2Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 1Burner Balm Responds to Barrage of UK Protests Over New Lip Balm 55340 2
...w vaccine aimed at preventing cervical cancer is n...of the human papillomavirus (HPV) responsible for ...wide study of the vaccine will be published in the...e. , Cervical cancer is the second most common cau...in nearly half a million diagnoses and 240,000 dea...
...scientific evidence is helping to build a compelli...adjunctive treatment for many cancers. , Reovir...lgary, Alberta-based Oncolytics Biotech, has shown...mor cells, in animal models, and in human clinical...ion, Reolysin®, is active against numerous cancers...
...archers at UNIVET, a spin-off of the Universitat A...al nutrition company Affinity Petcare, have develo...reproduces the characteristics of dog’s skin and w...rious lines of research related to skin biology an..., The basic structure of skin consists of an exter...
Other Biology News:Study shows continued success for new HPV vaccine against virus responsible for cervical cancer 2Dealing deadly cancers a knockout punch 2Dealing deadly cancers a knockout punch 3
Tricyclic Antidepressents ELISA Kit, Single from Bio-Quant Inc.
VZV IgM ELISA Kit, Single from Bio-Quant Inc.
Scion Image for Windows from Scion Corporation
...mbion's custom siRNA service provides the premium ...search. Custom siRNAs can be readily ordered onlin...ce, or by providing the sense and antisense siRNA ...ated and Silencer Pre-designed siRNAs, which are a...
Biology Products: